Walgreens' new integrated support program aims to help patients with cancer manage the side effects of undergoing treatment. Here’s five things to know about it.
Shah
A new program from pharmacy retail giant Walgreens provides personalized support to cancer patients by combining specially trained beauty consultants and pharmacists.
“Feel More Like You,” a cancer side-effect management program rolled out in 100 stores in seven metro areas in the spring, and the remaining stores participating will comprise beauty-differentiated stores throughout Florida. It is available at more than 400 retail stores nationwide.
Cancer will soon be the leading cause of death in the United States, according to a new study published in the Annals of Internal Medicine.
“Cancer has a major impact on patients in the U.S. and across the world,” says Rina Shah, vice president of pharmacy operations and specialty at Walgreens. “It’s more important than ever that healthcare organizations, and those who have a hand in shaping the future of patient care, look for new ways to address the evolving needs of patients. ‘Feel More Like You’ is an integrated approach to cancer care, with specially trained Walgreens beauty consultants and pharmacists working to provide personalized expertise to people living with cancer.”
Both cancer and cancer treatment can cause your body to change, according to the American Cancer Society. Besides hair loss, chemotherapy can cause side effects. Radiation also can cause hair loss, along with skin damage and other issues.
When a customer arrives in store, they will be able to receive on-site services from Walgreens beauty consultants and specially trained Walgreens pharmacists, according to Shah. Beauty consultants and pharmacists were also trained in collaboration with Look Good Feel Better, a non-profit organization that teaches beauty techniques to people living with cancer, and Cancer Support Community, the largest professionally-led nonprofit network of cancer support worldwide.
“The program was created in response to an increased number of oncology patients entering Walgreens pharmacies and the need for expert information,” says Shah. “. . . Walgreens has the unique position to provide free, accessible, and on-demand cancer resources at the point of care through the ‘Feel More Like You’ program. Walgreens is the first retailer to address the well-being of oncology patients by providing in-store pharmacy and beauty support to help people living with cancer manage both internal and external side effects of treatment. Caregivers and patients may be unsure where to go for help with holistic treatment both inside and out, and this program is focused on meeting that need.”
Currently, there is not a health plan component to the program, but from this initial pilot of 400 locations, Walgreens will be able to garner patient feedback and better assess what additional components are needed to evolve the program, according to Shah.
Here are five things to know about the “Feel More Like You” program:
Cancer’s Reign Over the Drug Development Pipeline Continues| AMCP Nexus 2024
October 18th 2024The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several months and in early 2025, according to Kaelyn Boss, who gave an oncology drug pipeline talk at the 2024 AMCP Nexus meeting this week.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Verastem Begins Submission for Ovarian Cancer Combination
May 24th 2024Verastem is studying the combination of avutometinib and defactinib to treat low-grade serous ovarian cancer in patients with KRAS-mutations. The company plans to complete the new drug application in the second half of this year.
Read More